Clinical Development

LipimetiX has completed Phase 1a and 1b/2a clinical studies with AEM-28. The results of these studies were announced in the September 2, 2014 and December 16, 2014 press releases by our joint venture partner, Capstone Therapeutics. AEM-28 demonstrated 75% reductions in VLDL cholesterol and triglycerides within 1 hour of administration in both the Phase 1a and 1b/2a studies, with similar efficacy after each of 3 repeated doses in Phase 1b/2a study.

As a result of the enhanced potency and extended patent lifeof AEM-28-14, LipimetiX plans to continue clinical development with this unique CHAMP. The figure below displays the current clinical development status of the CHAMP molecules.